KPIs & Operating Metrics(New)
Growth Metrics

Johnson & Johnson (JNJ) Income from Continuing Operations (2009 - 2026)

Johnson & Johnson recorded quarterly Income from Continuing Operations of 5235000000.0 in Q1 2026, up 2.33% quarter-over-quarter from 5116000000.0 in Q4 2025, and down 52.4% year-over-year from 10999000000.0 in Q1 2025.

Johnson & Johnson's Income from Continuing Operations history runs 18 years deep, the most recent figure standing at 5235000000.0 for Q1 2026.

  • In Q1 2026, Income from Continuing Operations fell 52.4% year-over-year to 5235000000.0; the TTM figure through Mar 2026 stood at 21040000000.0 (down 3.53% YoY), while the FY2025 annual figure was 26804000000.0, up 90.56% from the prior year.
  • Income from Continuing Operations came in at 5235000000.0 for Q1 2026 at Johnson & Johnson, up from 5116000000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 10999000000.0 in Q1 2025 to a low of 491000000.0 in Q2 2023.
  • A 5-year average of 4411647058.82 and a median of 4310000000.0 in 2022 frame the typical range for Income from Continuing Operations.
  • Across the five-year window, Income from Continuing Operations slumped 110.94% in 2023 and soared 762.93% in 2024, its largest moves.
  • Johnson & Johnson's Income from Continuing Operations stood at 4310000000.0 in 2022, then decreased by 4.13% to 4132000000.0 in 2023, then slipped by 16.97% to 3431000000.0 in 2024, then surged by 49.11% to 5116000000.0 in 2025, then increased by 2.33% to 5235000000.0 in 2026.
  • According to Business Quant data, Income from Continuing Operations over the past three periods registered 5235000000.0, 5116000000.0, and 5152000000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 7.40 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 5.24 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn 697.00 Mn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn -4.21 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 1.82 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 2.02 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn 2.71 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn 2.68 Bn
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 29, 2026 5.24 Bn
Dec 28, 2025 5.12 Bn
Sep 28, 2025 5.15 Bn
Jun 29, 2025 5.54 Bn
Mar 30, 2025 11.00 Bn
Dec 29, 2024 3.43 Bn
Sep 29, 2024 2.69 Bn
Jun 30, 2024 4.69 Bn
Mar 31, 2024 3.26 Bn
Dec 31, 2023 4.13 Bn
Oct 1, 2023 4.31 Bn
Jul 2, 2023 5.38 Bn
Apr 2, 2023 -491.00 Mn
Jan 1, 2023 2.65 Bn
Oct 2, 2022 4.31 Bn
Jul 3, 2022 4.12 Bn
Apr 3, 2022 4.49 Bn
Oct 3, 2021 3.67 Bn
Jul 4, 2021 6.28 Bn
Apr 4, 2021 6.20 Bn
Jan 3, 2021 1.74 Bn
Sep 27, 2020 3.55 Bn
Jun 28, 2020 3.63 Bn
Mar 29, 2020 5.80 Bn
Dec 29, 2019 4.01 Bn
Sep 29, 2019 1.75 Bn
Jun 30, 2019 5.61 Bn
Mar 31, 2019 3.75 Bn
Dec 30, 2018 3.04 Bn
Sep 30, 2018 3.93 Bn
Jul 1, 2018 3.95 Bn
Apr 1, 2018 4.37 Bn
Dec 31, 2017 -10.71 Bn
Oct 1, 2017 3.76 Bn
Jul 2, 2017 3.83 Bn
Apr 2, 2017 4.42 Bn
Jan 1, 2017 4.31 Bn
Oct 2, 2016 4.27 Bn
Jul 3, 2016 4.00 Bn
Apr 3, 2016 4.46 Bn
Jan 3, 2016 3.76 Bn
Sep 27, 2015 3.36 Bn
Jun 28, 2015 4.52 Bn
Mar 29, 2015 4.32 Bn
Dec 28, 2014 2.52 Bn
Sep 28, 2014 4.75 Bn
Jun 29, 2014 4.33 Bn
Mar 30, 2014 4.73 Bn
Dec 29, 2013 3.52 Bn
Sep 29, 2013 2.98 Bn
Jun 30, 2013 3.83 Bn
Mar 31, 2013 3.50 Bn
Dec 30, 2012 2.57 Bn
Sep 30, 2012 2.63 Bn
Jul 1, 2012 1.41 Bn
Apr 1, 2012 3.91 Bn
Jan 1, 2012 956.00 Mn
Oct 2, 2011 3.20 Bn
Jul 3, 2011 2.78 Bn
Apr 3, 2011 3.48 Bn
Jan 2, 2011 2.23 Bn
Oct 3, 2010 3.42 Bn
Jul 4, 2010 3.45 Bn
Apr 4, 2010 4.53 Bn
Jan 3, 2010 2.21 Bn
Sep 27, 2009 3.35 Bn
Jun 28, 2009 3.21 Bn
Mar 29, 2009 3.51 Bn